Comparison · NCT01429441-sae
Ocriplasmin vs Sham: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ocriplasmin vs Sham: serious adverse events. Trial comparisons, record NCT01429441-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01429441-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.336 | 0.264 | 0.416 | wilson | |
| Risk in group 2 | 0.365 | 0.264 | 0.479 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0292 | -0.164 | 0.0992 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.92 | 0.631 | 1.34 | log | |
| Odds ratio, group 1 over group 2 | 0.879 | 0.49 | 1.58 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Ocriplasmin than on Sham | 34.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: sham.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ocriplasmin | Subjects in the ocriplasmin group received a single intravitreal injection of ocriplasmin 0.125mg | 49 | 146 | EG000 |
| Group 2 | Sham | Subjects in the sham group received a single sham injection | 27 | 74 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were collected from the injection day (Day 0) up to discontinuation from the study or completion of the study (Month 24).
Source ClinicalTrials.gov
Trial
- Title
- Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
- NCT number
- NCT01429441
- Phases
- PHASE3
- Conditions
- Vitreomacular Adhesion Including Macular Hole
- Interventions
- Ocriplasmin, Sham injection
- Lead sponsor
- ThromboGenics
- Results first posted
- 2016-01-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01429441?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01429441-sae